Refractory sweet syndrome with autoimmune organizing pneumonia treated with monoclonal antibodies to tumor necrosis factor

Journal of Clinical Rheumatology

Volumn 10, Issue 6, 2004, Pages 331-335

  Karamlou, Kathy ^a   Gorn, Alan H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute febrile neutrophilic dermatoses; Adalimumab; Infliximab; Myelodysplastic syndrome; Organizing pneumonia; Sweet syndrome

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT; ANEMIA; ARTICLE; CASE REPORT; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PNEUMONIA; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME;

EID: 10044276849     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000147053.60795.46     Document Type: Article

References (27)

1. Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol. 1964;76:349-356.
2. Su WP, Liu HN. Diagnostic criteria for Sweet's syndrome. Cutis. 1986;37:167-174.
3. Bourke SJ, Quinn AG, Farr PM, et al. Neutrophilic alveolitis in Sweet's syndrome. Thorax. 1992;47:572-573.
4. Chien SM, Jambrosic J, Mintz S. Pulmonary manifestations in Sweet's syndrome: first report of a case with bronchiolitis obliterans organizing pneumonia. Am J Med. 1991;91:553-554.
5. Gibson LE, Dicken CH, Flach DB. Neutrophilic dermatoses and myeloproliferative disease: report of two cases. Mayo Clin Proc. 1985;60:737-740.
6. Ladani S, Kamble RT, Sundaram P, et al. Non responding pneumonia with skin lesions. Indian J Chest Allied Sci. 2001;43:115-117.
7. Lazarus AA, McMillan M, Miramadi A. Pulmonary involvement in Sweet's syndrome (acute febrile neutrophilic dermatosis) preleukemic and leukemic phases of acute myelogenous leukemia. Chest. 1986;90:922-924.
8. Longo MI, Pico M, Bueno C, et al. Sweet's syndrome and bronchiolitis obliterans organizing pneumonia. Am J Med. 2001;111:80-81.
9. Peters FJP, Drent M, Verhaegh M, et al. Myelodysplasia presenting with pulmonary manifestations associated with neutrophilic dermatosis. Ann Hematol. 1988;77:135-138.
10. Reid PT, Alderdice J, Carson J, et al. Cryptogenic organizing pneumonia in association with Sweet's syndrome. Respir Med. 1996;90:57-59.
11. Takimoto CH, Warnock M, Golden JA. Sweet's syndrome with lung involvement. Am Rev Respir Dis. 1991;143:177-179.
12. Thurnheer R, Stammberger U, Hailemariam S, et al. Bronchial manifestation of acute febrile neutrophilic dermatosis (Sweet's syndrome). Eur Respir J. 1998;11:978-980.
13. Von den Driesch P, Gomez RS, Kiesewetter F, et al. Sweet's syndrome: clinical spectrum and associated conditions. Cutis. 1989;44:193-200.
14. Honigsmann H, Cohen PR, Wolff K. Acute febrile neutrophilic dermatosis (Sweet's syndrome). In: Freedberg IM, Eisen AZ, Wolff K, et al., eds. Dermatology in General Medicine. New York: McGraw-Hill; 1999:1117-1123.
15. Von den Driesch P. Sweet's syndrome and vasculitis [Letter]. J Am Acad Dermatol. 1996;34:539.
16. Malone JC, Slone SP, Wills-Frank LA, et al. Vascular inflammation (vasculitis) in Sweet syndrome. Arch Dermatol. 2002;138:345-349.
17. Lipsky PE, Van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;30:1594-1602.
18. Tanaka N, Fujioku A, Tajima S, et al. Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1B and tumor necrosis factor alpha stimulates its secretion in vitro. Br J Dermatol. 2000;143:728-732.
19. Giasuddin AS, Abdul Hamed A, El-Orfi M, et al. Sweet's syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol. 1998;39:940-943.
20. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45.
21. Vanbiervliet G, Anty R, Schneider S, et al. Sweet's syndrome and erythema nodosum associated with Crohn's disease treated by infliximab. Gastroenterology Clin Biol. 2002;26:295-297.
22. Matzkies FG, Manger B, Schmitt-Haendle M, et al. Severe septicemias in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab. Ann Rheum Dis. 2003;62:81-82.
23. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86:268-276.
24. Mundle SD, Ali A, Cartlidge JD, et al. Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol. 1999;60:36-47.
25. Shetty V, Mundle S, Alvi S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res. 1996;20:891-900.
26. Stasi R, Amadori S. Infliximab chimeric anti-tumor necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol. 2002;116:334-337.
27. Maciejewski JP, Ristiano AM, Sloand EM, et al. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol. 2002;117:119.